Medicus Sciences Acquisition (MSAC) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 11, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Entity File Number	001-40068
Entity Registrant Name	MEDICUS SCIENCES ACQUISITION CORP.
Entity Incorporation, State or Country Code	KY
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	152 West 57th Street, Floor 20
Entity Address, City or Town	New York,
Entity Address State Or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	259-8400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Central Index Key	0001836517
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Class A ordinary shares
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary shares, $0.0001 par value
Trading Symbol	MSAC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		9,292,000
Class B ordinary shares
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		2,323,000
Redeemable Warrants Exercisable For Class Common Stock
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each warrant exercisable for one Class Aordinary share for $11.50 per share
Trading Symbol	MSACW
Security Exchange Name	NASDAQ

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 1,065,315	$ 1,433,753
Prepaid expenses	119,915	146,133
Due from Sponsor	118	118
Total current assets	1,185,348	1,580,004
Investments held in Trust Account	92,080,767	92,008,585
Derivative asset - forward purchase agreement	127,200	35,840
Total Assets	93,393,315	93,624,429
Current liabilities:
Accrued expenses	21,422	32,008
Total current liabilities	21,422	32,008
Deferred underwriting commissions	2,300,000	2,300,000
Derivative liability - warrants	1,892,587	5,935,328
Total liabilities	4,214,009	8,267,336
Commitments and Contingencies
Class A ordinary shares subject to possible redemption, $0.0001 par value; 9,200,000 shares issued and outstanding at redemption value of $10.01 and $10.00 per share as of June 30, 2022, and December 31, 2021, respectively	92,080,767	92,000,000
Shareholders' Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
Accumulated deficit	(2,901,702)	(6,643,148)
Total shareholders' deficit		(6,642,907)
Total Liabilities, Redeemable Ordinary Shares and Shareholders' Deficit	93,393,315	93,624,429
Class A ordinary shares
Shareholders' Deficit:
Ordinary shares	9	9
Class B ordinary shares
Shareholders' Deficit:
Ordinary shares	$ 232	$ 232

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preference shares, par value, (per share)	$ 0.0001	$ 0.0001
Preference shares, shares authorized	1,000,000	1,000,000
Preference shares, shares issued	0	0
Preference shares, shares outstanding	0	0
Class A ordinary shares
Ordinary shares, par value, (per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	200,000,000	200,000,000
Class A ordinary shares subject to possible redemption
Ordinary shares, shares subject to possible redemption, par value, (per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares subject to possible redemption, issued (in shares)	9,200,000	9,200,000
Ordinary shares, shares subject to possible redemption, outstanding (in shares)	9,200,000	9,200,000
Ordinary shares, shares subject to possible redemption value (per share)	$ 10.01	$ 10
Class A ordinary shares not subject to possible redemption
Ordinary shares, shares issued	92,000	92,000
Ordinary shares, shares outstanding	92,000	92,000
Class B ordinary shares
Ordinary shares, par value, (per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	20,000,000	20,000,000
Ordinary shares, shares issued	2,323,000	2,323,000
Ordinary shares, shares outstanding	2,323,000	2,323,000

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Formation and operating costs	$ 174,942	$ 192,428	$ 384,070	$ 301,794
Loss from operations	(174,942)	(192,428)	(384,070)	(301,794)
Other income (expense):
Interest earned on investments held in Trust Account	70,608	4,293	72,182	5,878
Offering costs allocated to warrants				(205,898)
Change in fair value of warrant liability and derivative asset - forward purchase agreement, net	1,673,968	(1,354,886)	4,134,101	405,151
Total other income (expense), net	1,744,576	(1,350,593)	4,206,283	205,131
Net income (loss)	1,569,634	(1,543,021)	3,822,213	(96,663)
Class A ordinary shares
Other income (expense):
Net income (loss)	$ 1,255,707	$ (1,234,417)	$ 3,057,770	$ (77,330)
Weighted average shares outstanding (Basic)	9,292,000	9,292,000	9,292,000	6,776,486
Basic net income (loss) per ordinary share	$ 0.14	$ (0.13)	$ 0.33	$ (0.01)
Weighted average shares outstanding (Diluted)	9,292,000	9,292,000	9,292,000	6,776,486
Diluted net income (loss) per ordinary share	$ 0.14	$ (0.13)	$ 0.33	$ (0.01)
Class B ordinary shares
Other income (expense):
Net income (loss)	$ 313,927	$ (308,604)	$ 764,443	$ (19,333)
Weighted average shares outstanding (Basic)	2,323,000	2,323,000	2,323,000	2,240,972
Basic net income (loss) per ordinary share	$ 0.14	$ (0.13)	$ 0.33	$ (0.01)
Weighted average shares outstanding (Diluted)	2,323,000	2,323,000	2,323,000	2,240,972
Diluted net income (loss) per ordinary share	$ 0.14	$ (0.13)	$ 0.33	$ (0.01)

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)	Class A ordinary shares Common Stock	Class A ordinary shares	Class B ordinary shares Common Stock	Class B ordinary shares	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at the beginning at Dec. 31, 2020			$ 232		$ 24,768	$ (6,068)	$ 18,932
Balance at the beginning (in shares) at Dec. 31, 2020			2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of representative shares	$ 9				911		920
Issuance of representative shares (in shares)	92,000
Accretion to redemption value for Class A ordinary shares subject to possible redemption					(25,679)	(8,534,957)	(8,560,636)
Net income (loss)						1,446,358	1,446,358
Balance at the end at Mar. 31, 2021	$ 9		$ 232			(7,094,667)	(7,094,426)
Balance at the end (in shares) at Mar. 31, 2021	92,000		2,323,000
Balance at the beginning at Dec. 31, 2020			$ 232		$ 24,768	(6,068)	18,932
Balance at the beginning (in shares) at Dec. 31, 2020			2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		$ (77,330)		$ (19,333)			(96,663)
Balance at the end at Jun. 30, 2021	$ 9		$ 232			(8,637,688)	(8,637,447)
Balance at the end (in shares) at Jun. 30, 2021	92,000		2,323,000
Balance at the beginning at Mar. 31, 2021	$ 9		$ 232			(7,094,667)	(7,094,426)
Balance at the beginning (in shares) at Mar. 31, 2021	92,000		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(1,234,417)		(308,604)		(1,543,021)	(1,543,021)
Balance at the end at Jun. 30, 2021	$ 9		$ 232			(8,637,688)	(8,637,447)
Balance at the end (in shares) at Jun. 30, 2021	92,000		2,323,000
Balance at the beginning at Dec. 31, 2021	$ 9		$ 232			(6,643,148)	(6,642,907)
Balance at the beginning (in shares) at Dec. 31, 2021	92,000		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)						2,252,579	2,252,579
Balance at the end at Mar. 31, 2022	$ 9		$ 232			(4,390,569)	(4,390,328)
Balance at the end (in shares) at Mar. 31, 2022	92,000		2,323,000
Balance at the beginning at Dec. 31, 2021	$ 9		$ 232			(6,643,148)	(6,642,907)
Balance at the beginning (in shares) at Dec. 31, 2021	92,000		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		3,057,770		764,443			3,822,213
Balance at the end at Jun. 30, 2022	$ 9		$ 232			(2,901,702)
Balance at the end (in shares) at Jun. 30, 2022	92,000		2,323,000
Balance at the beginning at Mar. 31, 2022	$ 9		$ 232			(4,390,569)	(4,390,328)
Balance at the beginning (in shares) at Mar. 31, 2022	92,000		2,323,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion to redemption value for Class A ordinary shares subject to possible redemption						(80,767)	(80,767)
Net income (loss)		$ 1,255,707		$ 313,927		1,569,634	$ 1,569,634
Balance at the end at Jun. 30, 2022	$ 9		$ 232			$ (2,901,702)
Balance at the end (in shares) at Jun. 30, 2022	92,000		2,323,000

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash flows from Operating Activities:
Net income (loss)			$ 3,822,213	$ (96,663)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Interest earned on investments held in Trust Account	$ (70,608)	$ (4,293)	(72,182)	(5,878)
Change in fair value of warrant liability and derivative asset - forward purchase agreement, net	(1,673,968)	1,354,886	(4,134,101)	(405,151)
Offering costs allocated to warrants				205,898
Changes in operating assets and liabilities:
Prepaid expenses			26,218	(258,176)
Due from Sponsor				(117)
Due to related party				25,714
Private placement proceeds received in advance				(2,000)
Accrued expenses			(10,586)
Net cash used in operating activities			(368,438)	(536,373)
Cash Flows from Investing Activities:
Investment held in Trust Account				(92,000,000)
Net cash used in investing activities				(92,000,000)
Cash flows from Financing Activities:
Proceeds from initial public offering				92,000,000
Proceeds from private placement				4,218,000
Payment of underwriter discount at IPO				(1,840,000)
Proceeds from promissory note - related party				215,715
Payment of deferred offering costs				(363,443)
Net cash provided by financing activities				94,230,272
Net change in cash			(368,438)	1,693,899
Cash, beginning of the period			1,433,753	2,000
Cash, end of the period	$ 1,065,315	$ 1,695,899	$ 1,065,315	1,695,899
Supplemental disclosure of noncash investing and financing activities:
Accrued offering costs				24,600
Deferred underwriting commissions payable charged to additional paid in capital				2,300,000
Initial measurement of forward purchase agreement liability				521,597
Repayment of promissory note - related party through reduction in proceeds from private placement				$ 300,000

Organization and Business Opera

Organization and Business Operations	6 Months Ended
	Jun. 30, 2022
Organization and Business Operations
Organization and Business Operations	Note 1 — Organization and Business Operations Medicus Sciences Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated in the Cayman Islands on November 26, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of June 30, 2022, the Company had not commenced any operations. All activity through June 30, 2022 relates to the Company’s formation and the Initial Public Offering (“IPO”), which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO. The registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 12, 2021 (the “Effective Date”). Simultaneously with the closing of the IPO, the Company consummated the sale of 5,022,222 private placement warrants (the “Private Placement Warrants”) to the Sponsor and Maxim Partners LLC (3,642,222 Private Placement Warrants to the Sponsor and 1,380,000 to Maxim Partners LLC) at a price of $0.90 per Private Placement Warrant, generating total gross proceeds of $4,520,000. Also, simultaneously with the closing of the IPO, the Company issued to designees of Maxim Partners LLC 92,000 shares of non-redeemable Class A ordinary shares (the “representative shares”). The Company estimated the fair value of the stock to be $920 based upon the price of the founder shares issued to the Sponsor. The representative shares were treated as underwriters’ compensation and charged directly to temporary equity. Transaction costs amounted to $4,677,181 consisting of $1,840,000 of underwriting discount, $2,300,000 of deferred underwriting discount, the fair value of the representative shares of $920 and $537,181 of other cash offering costs. Following the closing of the IPO on February 18, 2021, $92,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”) and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”) having a maturity of 185 days or less or in money market funds meeting certain conditions of Rule 2a-7 under the Investment Company Act which only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay the income taxes, if any, the Company’s amended and restated memorandum and articles of association will provide that the proceeds from the IPO and the sale of the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1) to the Company, until the completion of the initial Business Combination, or (2) to the public shareholders, until the earliest of (a) the completion of the initial Business Combination, and then only in connection with those Class A ordinary shares that such shareholders properly elected to redeem, subject to the limitations, (b) the redemption of any Public Shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to provide holders of the Company’s Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete the initial Business Combination within 24 months from the closing of the IPO (the “Combination Period”), or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares, and (c) the redemption of the Public Shares if the Company has not consummated the initial Business Combination within the Combination Period. Public shareholders who redeem their Class A ordinary shares in connection with a shareholder vote described in clause (b) in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within the Combination Period, with respect to such Class A ordinary shares so redeemed. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the public shareholders. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s financial position will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s financial position may be materially adversely affected. Additionally, the Company’s ability to complete an initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an initial Business Combination in a timely manner. The Company’s ability to consummate an initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these condensed financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these condensed financial statements. Going Concern In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has until February 18, 2023 to consummate the proposed Business Combination. It is uncertain that the Company will be able to consummate the proposed Business Combination by this time. If a Business Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the mandatory liquidation, should a business combination not occur, and potential subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 18, 2023. The Company intends to complete the proposed Business Combination before the mandatory liquidation date. However, there can be no assurance that the Company will be able to consummate any business combination by February 18, 2023.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Significant Accounting Policies	Note 2 — Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented The accompanying condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2022. Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents in its operating account as of June 30, 2022 and December 31, 2021. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. As of June 30, 2022, and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Warrant Liabilities and Derivative Assets - Forward Purchase Agreement The Company accounts for the Warrants and its Forward Purchase Agreement (“FPA”) as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and FPA and the applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the Warrants and FPA are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and FPA are indexed to the Company’s own ordinary shares and whether the Warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and execution of the FPA and as of each subsequent quarterly period end date while the Warrants and FPA are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Warrants and FPA in accordance with ASC 815-40 under which the Warrants and FPA do not meet the criteria for equity classification and must be recorded as derivatives. The fair value of the Public Warrants has been estimated using its quoted market price as of June 30, 2022. The fair value of the Private Placement Warrants has been estimated using the modified Black-Scholes-Merton model. The fair value of the FPA has been estimated using an adjusted net assets method. See Note 9 for further discussion of the fair value measurement. As the Warrants and FPA meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities and the FPA is recorded as derivative assets on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company allocates the offering costs between ordinary share and Warrants using a relative fair value method, pursuant to which the offering costs allocated to the Public Warrants will be expensed immediately. Offering costs were allocated on a relative fair value basis between temporary equity and expense. The portion of offering costs allocated to the Public Warrants has been charged to expense. The portion of offering costs allocated to the Public Shares were initially charged to temporary equity and then accreted to Class A ordinary shares subject to redemption upon the completion of the IPO. Accordingly, as of June 30, 2022, offering costs amounted to $4,678,101, of which $4,472,203 were charged to temporary equity upon the completion of the IPO and $205,898 were expensed to the condensed statement of operations. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. Most of the Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 9,200,000 Class A ordinary shares subject to possible redemption were presented as temporary equity, outside of the shareholders’ deficit section of the Company’s unaudited condensed balance sheets. Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”). ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for the financial statements’ recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. Net Income (Loss) Per Ordinary Share Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the Warrants sold in the IPO and Private Placement (as defined below) to purchase an aggregate of 8,088,889 Class A ordinary shares in the calculation of diluted income (loss) per ordinary share, since their exercise is contingent. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. As a result, diluted income (loss) per ordinary share is the same as basic income (loss) per ordinary share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Three Months Ended ​ Six Months Ended ​ Six Months Ended ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ Class A Class B Class A Class B Class A Class B Class A Class B Allocation of net income (loss) ​ $ 1,255,707 ​ $ 313,927 ​ $ (1,234,417) ​ ​ (308,604) ​ $ 3,057,770 ​ $ 764,443 ​ $ (77,330) ​ $ (19,333) Basic and Diluted Weighted Average Ordinary Shares outstanding ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 6,776,486 ​ 2,240,972 Basic and Diluted net income (loss) per ordinary share ​ $ 0.14 ​ $ 0.14 ​ $ (0.13) ​ $ (0.13) ​ $ 0.33 ​ $ 0.33 ​ $ (0.01) ​ $ (0.01) ​ Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. As of June 30, 2022 and December 31, 2021, the carrying values of cash, prepaid expenses, and current liabilities approximate their fair values due to the short-term nature of the instruments. See Note 9 for additional information on assets and liabilities measured at fair value on a recurring basis. Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements.

IPO

IPO	6 Months Ended
	Jun. 30, 2022
IPO
IPO	Note 3 — IPO On February 18, 2021, the Company sold 9,200,000 Units, at a purchase price of $10.00 per Unit, which included the full exercise by the underwriters of the over-allotment option to purchase an additional 1,200,000 Units. Each Unit consists of one Class A ordinary share, one two All of the 9,200,000 Class A ordinary shares sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. Given that the Class A ordinary share was issued with other freestanding instruments (i.e., Public Warrants), the initial carrying value of Class A ordinary share classified as temporary equity is the allocated proceeds based on the guidance in ASC 470-20. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable Class A ordinary shares resulted in charges against additional paid-in capital and accumulated deficit. The Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets are reconciled in the following table: ​ ​ ​ ​ ​ Gross proceeds from public issuance $ 92,000,000 Less: ​ Proceeds allocated to Public Warrants ​ (4,089,353) Class A ordinary shares issuance costs ​ (4,471,283) Plus: ​ Accretion of carrying value to redemption value ​ 8,560,636 Class A ordinary shares subject to possible redemption, December 31, 2021 ​ ​ 92,000,000 Plus: ​ ​ ​ Accretion of carrying value to redemption value ​ ​ 80,767 Class A ordinary shares subject to possible redemption, June 30, 2022 ​ $ 92,080,767 ​

Private Placement

Private Placement	6 Months Ended
	Jun. 30, 2022
Private Placement.
Private Placement	Note 4 — Private Placement Simultaneously with the closing of the IPO, the Sponsor and Maxim Partners LLC purchased an aggregate of 5,022,222 Private Placement Warrants (3,642,222 Private Placement Warrants by the Sponsor and 1,380,000 by Maxim Partners LLC) at a price of $0.90 per Private Placement Warrant, for an aggregate purchase price of $4,520,000, in a private placement (the “Private Placement”). These Private Placement Warrants are also exercisable to purchase one Class A ordinary share at $11.50 per share and are identical to the warrants being sold as part of the Units in the IPO, subject to certain limited exceptions. If the Company does not consummate an initial Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. The Private Placement Warrants (i) will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor, Maxim Partners LLC or their permitted transferees. If the Private Placement Warrants are held by holders other than the Sponsor, Maxim Partners LLC or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Warrants included in the Units being sold in the IPO.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	Note 5 — Related Party Transactions Founder Shares The Sponsor paid $25,000 of expenses on behalf of the Company in exchange for 2,323,000 shares of the Company’s Class B ordinary shares, or approximately $0.01 per share, in connection with formation. The founder shares included an aggregate of up to 303,000 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full. On February 18, 2021, the underwriter exercised the over-allotment option in full, hence, the 303,000 founder shares are no longer subject to forfeiture. The Sponsor and each member of the Company’s management team have agreed to waive their rights to liquidating distributions from the Trust Account with respect to any founder shares they hold if the Company fails to consummate an initial Business Combination within the Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to consummate an initial Business Combination within the Combination Period). The Sponsor has agreed not to transfer, assign or sell (i) any of their founder shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii) any of their Private Placement Warrants and Class A ordinary shares issued upon conversion or exercise thereof until 30 days after the completion of the initial Business Combination. Promissory Note — Related Party On December 7, 2020, the Company issued an unsecured promissory note to the Sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the IPO. This loan was non-interest bearing, unsecured and due at the earlier of June 30, 2021 or the closing of the IPO. The outstanding balance of $300,000 under the promissory note was repaid through a reduction in the Private Placement proceeds received from the Sponsor at the closing of the IPO and Private Placement on February 18, 2021. As of June 30, 2022, there was no remaining amount outstanding. The Company no longer has the ability to borrow under this arrangement. Working Capital Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $2,000,000 of such Working Capital Loans may be convertible upon consummation of the Business Combination into additional Private Placement Warrants at a price of $0.90 per warrant. The warrants would be identical to the Private Placement Warrants, including as to exercise price, exercisability and exercise period. As of June 30, 2022 and December 31, 2021, there were no amounts outstanding under the Working Capital Loans. Administrative Service Fee Commencing on the Effective Date, the Company has agreed to pay an affiliate of the Company’s Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of the Company’s Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three and six months ended June 30, 2022 and 2021, the Company has incurred and paid $30,000 and $60,000 of administrative service fee, respectively. For the three and six months ended June 30, 2021, the Company has incurred $30,000 and $45,714 of administrative service fee, respectively. As of June 30, 2022 and December 31, 2021 there were no amounts due or outstanding. Forward Purchase Agreement Upon closing of the IPO, the Company entered into an FPA, as amended with funds affiliated with Altium Capital Management, LP and Sio Capital Management, LLC (collectively, the “Forward Purchasers”). Pursuant to the FPA, the Forward Purchasers have agreed to purchase an aggregate of up to $16,000,000 of units (the “Forward Purchase Units”, the Class A ordinary shares and warrants constituting the Forward Purchase Units referred to as the “Forward Purchase Shares” and “Forward Purchase Warrants,” respectively, and collectively with the Class A ordinary shares underlying the Forward Purchase Warrants, the “Forward Purchase Securities”), which will have a purchase price of $10.00 per Forward Purchase Unit and consist of one Class A ordinary share and one-third of one warrant. The purchase of the 1,600,000 Forward Purchase Units will take place in a private placement substantially concurrently with the closing of the initial Business Combination. The Forward Purchasers have no obligation to purchase the Forward Purchase Units unless proceeds from sale of the Forward Purchase Units are necessary to enable the Company to complete the initial Business Combination. In that event, the Forward Purchasers’ obligation to purchase the Forward Purchase Units is limited to the purchase amount necessary to provide the Company with sufficient funds to consummate the initial Business Combination and to pay related fees and expenses, after first applying amounts available to the Company from the Trust Account (after giving effect to any redemptions of Public Shares) and any other equity financing source obtained by the Company for such purpose at or prior to the consummation of the initial Business Combination, plus any additional amounts mutually agreed and the target company to be retained by the post-business combination company for working capital or other purposes. In the event less than the full amount of the Forward Purchase Units is purchased, the Forward Purchasers will participate in the forward purchase proportionally. In addition, to the extent that the Forward Purchasers offer a bridge loan or any other form of financing to a target company in connection with a proposed initial business combination between the Company and that target company, the Forward Purchasers’ forward purchase obligation shall be reduced by the amount of such loan or other financing. The Forward Purchasers’ obligation to purchase the Forward Purchase Units may not be transferred to any other parties. The proceeds of any sales of Forward Purchase Units will not be deposited in the Trust Account. The terms of the Forward Purchase Shares and Forward Purchase Warrants, respectively, will be identical to the terms of the Class A ordinary shares and the Redeemable Warrants included in the Units being issued in the IPO except that they will be subject to certain transfer restrictions and have certain registration rights. The Company has classified the FPA as a derivative. This financial instrument is subject to re-measurement at each balance sheet date. With each such re-measurement, the FPA asset or liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. As such, the Company recorded a $521,597 derivate liability related to the FPA as of February 18, 2021. At June 30, 2022 and 2021, the re-measurement of the derivative associated with the FPA resulted in a derivative asset, and accordingly, for the three and six months ended June 30, 2022, the Company recorded a change in the fair value of the derivate instrument associated with the FPA as other income of $91,360 and $73,760, respectively, on the statements of operations, resulting in a derivative $127,220

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies.
Commitments and Contingencies	Note 6 — Commitments and Contingencies Registration Rights The holders of the founder shares, Private Placement Warrants, Forward Purchase Securities and warrants that may be issued upon conversion of Working Capital Loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement signed on February 12, 2021. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. Underwriting Agreement The underwriters were paid a cash underwriting discount of 2.0% of the gross proceeds of the IPO, or $1,840,000 in the aggregate, upon closing of the IPO and the over-allotment option. Additionally, the underwriters will be entitled to a deferred underwriting discount of 2.5% of the gross proceeds of the IPO held in the Trust Account, or $2,300,000 upon the completion of the Company’s initial Business Combination subject to the terms of the underwriting agreement. Representative Shares On February 18, 2021, the Company issued to Maxim Partners LLC, a designee of Maxim Group LLC 92,000 non-redeemable Class A ordinary shares. The Company estimated the fair value of the stock to be $920 based upon the price of the founder shares issued to the Sponsor. The representative shares were treated as underwriters’ compensation and charged directly to shareholders’ equity. Maxim Partners LLC has agreed not to transfer, assign or sell any such shares until the completion of the initial Business Combination. In addition, Maxim Partners LLC has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the initial Business Combination within 24 months from the closing of the IPO.

Derivative Liability

Derivative Liability	6 Months Ended
	Jun. 30, 2022
Derivative Liability.
Derivative Liability	Note 7 — Derivative Liability As of June 30, 2022 and December 31, 2021, the Company has outstanding warrants to purchase an aggregate of 8,088,888 shares of the Company’s ordinary shares issued in connection with the IPO and the Private Placement (including warrants issued in connection with the consummation of the over-allotment option). Each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment as discussed herein. The warrants will become exercisable on the later of 30 days after the completion of the initial Business Combination or 12 months from the closing of the IPO and will expire five years after the completion of the initial Business Combination, or earlier upon redemption or liquidation. The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a Redeemable Warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the Redeemable Warrants is then effective and a prospectus relating thereto is current. No Redeemable Warrant will be exercisable, and the Company will not be obligated to issue Class A ordinary shares upon exercise of a warrant unless Class A ordinary shares issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the Redeemable Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Redeemable Warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any Redeemable Warrant. In the event that a registration statement is not effective for the exercised Redeemable Warrants, the purchaser of a Unit containing such Redeemable Warrant will have paid the full purchase price for the Unit solely for the Class A ordinary share underlying such Unit. In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or its affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company completes the initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described below under the heading “Redemption of Redeemable Warrants when the price per Class A ordinary share equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of 100% of the Market Value and the Newly Issued Price. The Forward Purchase Warrants will have the same exercise price as the Redeemable Warrants and be subject to the same price adjustments described above. If the Company’s Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Redeemable Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but the Company will be required to use commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) less the exercise price of the warrants by (y) the fair market value and (B) 0.3611 per Redeemable Warrant. The “fair market value” as used in this paragraph shall mean the average of the daily volume-weighted average trading prices of the Class A ordinary shares during the 10 consecutive trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00 . Once the warrants become exercisable, the Company may call the Redeemable Warrants (and the Forward Purchase Warrants) for redemption: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days ’ prior written notice of redemption to each warrant holder, provided that holders will be able to exercise their warrants prior to the time of redemption and, at the Company’ election, any such exercise may be required to be on a cashless basis; and ● if, and only if, the daily volume-weighted average price of the Class A ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a 30-trading-day period ending three trading days before the Company sends the notice of redemption to the warrant holders. Redemption of warrants when the price per Class A ordinary share equals or exceeds $10.00 . ● in whole and not in part; ● at $0.10 per warrant upon a minimum of 30 days ’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table described in the prospectus, based on the redemption date and the “fair market value” of the Company’s Class A ordinary shares; and ● if, and only if, the daily volume-weighted average price of the Company’s Class A ordinary shares equals or exceeds $10.00 per public share for any 20 trading days within the 30-trading-day period ending three trading days before the Company sends the notice of redemption to the warrant holders. The warrant agreement contains an Alternative Issuance provision that if less than 70% of the consideration receivable by the holders of the ordinary shares in the Business Combination is payable in the form of common equity in the successor entity, and if the holders of the warrants properly exercises the warrants within thirty days following the public disclosure of the consummation of Business Combination by the Company, the warrant price shall be reduced by an amount equal to the difference (but in no event less than zero) of (i) the warrant price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the Business Combination based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets. “Per Share Consideration” means (i) if the consideration paid to holders of the ordinary shares consists exclusively of cash, the amount of such cash per ordinary shares, and (ii) in all other cases, the volume weighted average price of the ordinary shares as reported during the ten-trading day period ending on the trading day prior to the effective date of the Business Combination. The Company believes that the adjustments to the exercise price of the warrants is based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815 – 40, and thus the warrants are not eligible for an exception from derivative accounting. The accounting treatment of derivative financial instruments requires that the Company record a derivative asset or liability upon the closing of IPO. Accordingly, the Company has classified each warrant as a liability at its fair value and the warrants were allocated a portion of the proceeds from the issuance of the Units equal to its fair value determined by the Monte Carlo simulation and Black-Scholes Option Pricing Model. This liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in the Company’s statement of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. As such, the Company recorded $10,851,878 of warrant liabilities upon issuance as of February 18, 2021. For the three months ended June 30, 2022, the Company recorded a change in the fair value of the warrant liabilities as a decrease in the amount of $1,600,208 on the statement The change in fair value of the warrant liabilities is summarized as follows: ​ ​ ​ ​ ​ Warrant liabilities at February 18, 2021 $ 10,851,878 Change in fair value of warrant liabilities ​ (2,639,529) Warrant liabilities at June 30, 2021 ​ $ 8,212,349 Change in fair value of warrant liabilities ​ ​ (2,277,021) Warrant liabilities at December 31, 2021 ​ $ 5,935,328 Change in fair value of warrant liabilities ​ ​ (2,442,533) Warrant liabilities at March 31, 2022 ​ $ 3,492,795 Change in fair value of warrant liabilities ​ ​ (1,600,208) Warrant liabilities at June 30, 2022 ​ $ 1,892,587 ​

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2022
Shareholders' Deficit
Shareholders' Deficit	Note 8 — Shareholders’ Deficit Preference Shares Class A Ordinary Shares Class B Ordinary Shares The Company’s Sponsor and management team have agreed not to transfer, assign or sell any of their founder shares until the earliest of (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the public shareholders having the right to exchange their ordinary shares for cash, securities or other property. The founder shares will automatically convert into Class A ordinary shares on the first business day following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of (i) the total number of ordinary shares issued and outstanding upon completion of the IPO, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination (including the Forward Purchase Shares), excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, members of the Company’s management team or any of their affiliates upon conversion of Working Capital Loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one. The holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders except as required by law.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements
Fair Value Measurements	Note 9 — Fair Value Measurements The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices In Significant Other ​ Significant Other ​ ​ ​ ​ ​ Active Markets ​ Observable Inputs ​ Unobservable Inputs ​ June 30, 2022 (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Money Market held in Trust Account ​ $ 92,080,767 $ 92,080,767 $ — $ — Derivative asset - forward purchase agreement ​ 127,200 ​ ​ — ​ ​ — ​ ​ 127,200 ​ $ 92,207,967 $ 92,080,767 $ — $ 127,200 Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability - Public ​ $ 235,112 ​ $ — ​ $ 235,111 ​ $ — Warrant Liability – Private ​ ​ 1,657,475 ​ ​ — ​ ​ — ​ ​ 1,657,475 ​ $ 1,892,587 $ — $ 235,111 $ 1,657,475 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices In Significant Other Significant Other ​ ​ December 31, ​ Active Markets ​ Observable Inputs ​ Unobservable Inputs ​ ​ 2021 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ U.S. Money Market held in Trust Account ​ $ 92,008,585 ​ $ 92,008,585 ​ $ — ​ $ — Derivative asset - forward purchase agreement ​ 35,840 ​ — ​ — ​ 35,840 ​ ​ $ 92,044,425 ​ $ 92,008,585 ​ $ — ​ $ 35,840 Liabilities: ​ ​ ​ ​ Warrant Liability - Public ​ $ 746,324 ​ $ 746,324 ​ $ — ​ $ — Warrant Liability – Private ​ 5,189,004 ​ — ​ — ​ 5,189,004 ​ ​ $ 5,935,328 ​ $ 746,324 ​ $ — ​ $ 5,189,004 ​ At June 30, 2022 and December 31, 2021, the estimated fair value of the warrant liability for the Private Placement Warrants and the derivate asset – forward purchase agreement is determined using Level 3 inputs. Inherent in a Black-Scholes pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. The following table provides quantitative information regarding Level 3 fair value measurements as of June 30, 2022, December 31, 2021, and February 18, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ Public and Private Placement Warrants ​ 2022 2021 Exercise price ​ $ 11.5 ​ $ 11.5 ​ Share price ​ $ 9.78 ​ $ 9.72 ​ Volatility ​ 2.7 % ​ 12.1 % Expected life ​ 5.32 ​ ​ 5.57 ​ Risk-free rate ​ 3.01 % ​ 1.31 % Dividend yield ​ — % ​ — % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ Forward Purchase Agreement 2022 2021 Share price $ 9.78 $ 9.72 ​ Forward Purchase Price $ 10.00 $ 10.00 ​ Expected life ​ 0.32 ​ 0.57 ​ Risk-free rate ​ 1.94 % 0.22 % NPV of Per-Share Commitment $ 9.94 $ 9.99 ​ ​ The primary significant unobservable input used in the fair value measurement of the Company’s Private Placement Warrants is the expected volatility of the ordinary shares. Significant increases (decreases) in the expected volatility in isolation would result in a significantly higher (lower) fair value measurement. ​ The following table provides a reconciliation of changes in fair value of the beginning and ending balances for the liabilities classified as Level 3: ​ ​ ​ ​ ​ ​ Derivative Liabilities Fair value at December 31, 2020 $ — Initial value of public and private warrant liabilities at February 18, 2021 10,851,878 Initial value of FPA at February 18, 2021 521,597 Change in fair value ​ ​ (2,639,529) Fair value at June 30, 2021 ​ ​ 8,212,349 Public Warrants reclassified to level 1 (891,000) Change in fair value (2,132,345) Fair value at December 31, 2021 ​ ​ 5,189,004 Change in fair value ​ ​ (2,132,084) Fair Value at March 31, 2022 ​ ​ 3,056,920 Change in fair value ​ ​ (1,399,445) Fair Value at June 30, 2022 $ 1,657,475 ​ Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in April 2021 when the Public Warrants were separately listed and traded amounted to approximately $891,000. ​ The following table presents the changes in the fair value of FPA Derivative (Asset) liability: ​ ​ ​ ​ ​ Derivate liability - forward purchase agreement at February 18, 2021 $ (521,597) Change in fair value of derivate instrument related to forward purchase agreement ​ ​ 529,744 Derivative asset - forward purchase agreement at June 30, 2021 ​ $ 8,147 Change in fair value of derivate instrument related to forward purchase agreement ​ 27,693 Derivative asset - forward purchase agreement at December 31, 2021 ​ $ 35,840 Change in fair value of derivate instrument related to forward purchase agreement ​ 17,600 Derivative asset - forward purchase agreement at March 31, 2022 ​ $ 53,440 Change in fair value of derivate instrument related to forward purchase agreement ​ ​ 73,760 Derivative asset - forward purchase agreement at June 30, 2022 ​ $ 127,200 ​

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events
Subsequent Events	Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented The accompanying condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included Annual Report on Form 10-K filed by the Company with the SEC on March 31, 2022.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and, accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents in its operating account as of June 30, 2022 and December 31, 2021.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. As of June 30, 2022, and December 31, 2021, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.
Warrant Liabilities and Derivate Assets - Forward Purchase Agreement	Warrant Liabilities and Derivative Assets - Forward Purchase Agreement The Company accounts for the Warrants and its Forward Purchase Agreement (“FPA”) as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the Warrants and FPA and the applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”), and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the Warrants and FPA are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants and FPA are indexed to the Company’s own ordinary shares and whether the Warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and execution of the FPA and as of each subsequent quarterly period end date while the Warrants and FPA are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, such warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of liability-classified warrants are recognized as a non-cash gain or loss on the statements of operations. The Company accounts for the Warrants and FPA in accordance with ASC 815-40 under which the Warrants and FPA do not meet the criteria for equity classification and must be recorded as derivatives. The fair value of the Public Warrants has been estimated using its quoted market price as of June 30, 2022. The fair value of the Private Placement Warrants has been estimated using the modified Black-Scholes-Merton model. The fair value of the FPA has been estimated using an adjusted net assets method. See Note 9 for further discussion of the fair value measurement. As the Warrants and FPA meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities and the FPA is recorded as derivative assets on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change.
Offering Costs Associated with the Initial Public Offering	Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the IPO that were directly related to the IPO. The Company allocates the offering costs between ordinary share and Warrants using a relative fair value method, pursuant to which the offering costs allocated to the Public Warrants will be expensed immediately. Offering costs were allocated on a relative fair value basis between temporary equity and expense. The portion of offering costs allocated to the Public Warrants has been charged to expense. The portion of offering costs allocated to the Public Shares were initially charged to temporary equity and then accreted to Class A ordinary shares subject to redemption upon the completion of the IPO. Accordingly, as of June 30, 2022, offering costs amounted to $4,678,101, of which $4,472,203 were charged to temporary equity upon the completion of the IPO and $205,898 were expensed to the condensed statement of operations.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Class A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A ordinary shares are classified as shareholders’ equity. Most of the Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, 9,200,000 Class A ordinary shares subject to possible redemption were presented as temporary equity, outside of the shareholders’ deficit section of the Company’s unaudited condensed balance sheets.
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740, “Income Taxes” (“ASC 740”). ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for the financial statements’ recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the periods presented. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements.
Net Income (Loss) Per Ordinary Share	Net Income (Loss) Per Ordinary Share Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the Warrants sold in the IPO and Private Placement (as defined below) to purchase an aggregate of 8,088,889 Class A ordinary shares in the calculation of diluted income (loss) per ordinary share, since their exercise is contingent. Accretion associated with the redeemable Class A ordinary shares is excluded from earnings per share as the redemption value approximates fair value. As a result, diluted income (loss) per ordinary share is the same as basic income (loss) per ordinary share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Three Months Ended ​ Six Months Ended ​ Six Months Ended ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ Class A Class B Class A Class B Class A Class B Class A Class B Allocation of net income (loss) ​ $ 1,255,707 ​ $ 313,927 ​ $ (1,234,417) ​ ​ (308,604) ​ $ 3,057,770 ​ $ 764,443 ​ $ (77,330) ​ $ (19,333) Basic and Diluted Weighted Average Ordinary Shares outstanding ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 6,776,486 ​ 2,240,972 Basic and Diluted net income (loss) per ordinary share ​ $ 0.14 ​ $ 0.14 ​ $ (0.13) ​ $ (0.13) ​ $ 0.33 ​ $ 0.33 ​ $ (0.01) ​ $ (0.01) ​
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. As of June 30, 2022 and December 31, 2021, the carrying values of cash, prepaid expenses, and current liabilities approximate their fair values due to the short-term nature of the instruments. See Note 9 for additional information on assets and liabilities measured at fair value on a recurring basis.
Recent Accounting Standards	Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows. Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Significant Accounting Policies
Schedule of basic and diluted net income (loss) per ordinary share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Three Months Ended ​ Six Months Ended ​ Six Months Ended ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ Class A Class B Class A Class B Class A Class B Class A Class B Allocation of net income (loss) ​ $ 1,255,707 ​ $ 313,927 ​ $ (1,234,417) ​ ​ (308,604) ​ $ 3,057,770 ​ $ 764,443 ​ $ (77,330) ​ $ (19,333) Basic and Diluted Weighted Average Ordinary Shares outstanding ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 9,292,000 ​ 2,323,000 ​ 6,776,486 ​ 2,240,972 Basic and Diluted net income (loss) per ordinary share ​ $ 0.14 ​ $ 0.14 ​ $ (0.13) ​ $ (0.13) ​ $ 0.33 ​ $ 0.33 ​ $ (0.01) ​ $ (0.01) ​

IPO (Tables)

IPO (Tables)	6 Months Ended
	Jun. 30, 2022
IPO
Schedule of redeemable ordinary shares subject to possible redemption reflected on the balance sheet	The Class A ordinary shares subject to possible redemption reflected on the condensed balance sheets are reconciled in the following table: ​ ​ ​ ​ ​ Gross proceeds from public issuance $ 92,000,000 Less: ​ Proceeds allocated to Public Warrants ​ (4,089,353) Class A ordinary shares issuance costs ​ (4,471,283) Plus: ​ Accretion of carrying value to redemption value ​ 8,560,636 Class A ordinary shares subject to possible redemption, December 31, 2021 ​ ​ 92,000,000 Plus: ​ ​ ​ Accretion of carrying value to redemption value ​ ​ 80,767 Class A ordinary shares subject to possible redemption, June 30, 2022 ​ $ 92,080,767

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended
	Jun. 30, 2022
Warrants liabilities
Schedule of change in the fair value of the warrant liabilities	The change in fair value of the warrant liabilities is summarized as follows: ​ ​ ​ ​ ​ Warrant liabilities at February 18, 2021 $ 10,851,878 Change in fair value of warrant liabilities ​ (2,639,529) Warrant liabilities at June 30, 2021 ​ $ 8,212,349 Change in fair value of warrant liabilities ​ ​ (2,277,021) Warrant liabilities at December 31, 2021 ​ $ 5,935,328 Change in fair value of warrant liabilities ​ ​ (2,442,533) Warrant liabilities at March 31, 2022 ​ $ 3,492,795 Change in fair value of warrant liabilities ​ ​ (1,600,208) Warrant liabilities at June 30, 2022 ​ $ 1,892,587

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of company's assets that are measured at fair value on a recurring basis	The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices In Significant Other ​ Significant Other ​ ​ ​ ​ ​ Active Markets ​ Observable Inputs ​ Unobservable Inputs ​ June 30, 2022 (Level 1) (Level 2) (Level 3) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ U.S. Money Market held in Trust Account ​ $ 92,080,767 $ 92,080,767 $ — $ — Derivative asset - forward purchase agreement ​ 127,200 ​ ​ — ​ ​ — ​ ​ 127,200 ​ $ 92,207,967 $ 92,080,767 $ — $ 127,200 Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability - Public ​ $ 235,112 ​ $ — ​ $ 235,111 ​ $ — Warrant Liability – Private ​ ​ 1,657,475 ​ ​ — ​ ​ — ​ ​ 1,657,475 ​ $ 1,892,587 $ — $ 235,111 $ 1,657,475 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Quoted Prices In Significant Other Significant Other ​ ​ December 31, ​ Active Markets ​ Observable Inputs ​ Unobservable Inputs ​ ​ 2021 ​ (Level 1) ​ (Level 2) ​ (Level 3) Assets: ​ ​ ​ ​ U.S. Money Market held in Trust Account ​ $ 92,008,585 ​ $ 92,008,585 ​ $ — ​ $ — Derivative asset - forward purchase agreement ​ 35,840 ​ — ​ — ​ 35,840 ​ ​ $ 92,044,425 ​ $ 92,008,585 ​ $ — ​ $ 35,840 Liabilities: ​ ​ ​ ​ Warrant Liability - Public ​ $ 746,324 ​ $ 746,324 ​ $ — ​ $ — Warrant Liability – Private ​ 5,189,004 ​ — ​ — ​ 5,189,004 ​ ​ $ 5,935,328 ​ $ 746,324 ​ $ — ​ $ 5,189,004
Schedule of quantitative information regarding Level 3 fair value measurements inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ Public and Private Placement Warrants ​ 2022 2021 Exercise price ​ $ 11.5 ​ $ 11.5 ​ Share price ​ $ 9.78 ​ $ 9.72 ​ Volatility ​ 2.7 % ​ 12.1 % Expected life ​ 5.32 ​ ​ 5.57 ​ Risk-free rate ​ 3.01 % ​ 1.31 % Dividend yield ​ — % ​ — %
Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of reconciliation of changes in fair value of the beginning and ending balances for the liabilities	​ ​ ​ ​ ​ Derivative Liabilities Fair value at December 31, 2020 $ — Initial value of public and private warrant liabilities at February 18, 2021 10,851,878 Initial value of FPA at February 18, 2021 521,597 Change in fair value ​ ​ (2,639,529) Fair value at June 30, 2021 ​ ​ 8,212,349 Public Warrants reclassified to level 1 (891,000) Change in fair value (2,132,345) Fair value at December 31, 2021 ​ ​ 5,189,004 Change in fair value ​ ​ (2,132,084) Fair Value at March 31, 2022 ​ ​ 3,056,920 Change in fair value ​ ​ (1,399,445) Fair Value at June 30, 2022 $ 1,657,475
Forward Purchase Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Schedule of quantitative information regarding Level 3 fair value measurements inputs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ Forward Purchase Agreement 2022 2021 Share price $ 9.78 $ 9.72 ​ Forward Purchase Price $ 10.00 $ 10.00 ​ Expected life ​ 0.32 ​ 0.57 ​ Risk-free rate ​ 1.94 % 0.22 % NPV of Per-Share Commitment $ 9.94 $ 9.99 ​
Schedule of reconciliation of changes in fair value of the beginning and ending balances for the liabilities	​ ​ ​ ​ Derivate liability - forward purchase agreement at February 18, 2021 $ (521,597) Change in fair value of derivate instrument related to forward purchase agreement ​ ​ 529,744 Derivative asset - forward purchase agreement at June 30, 2021 ​ $ 8,147 Change in fair value of derivate instrument related to forward purchase agreement ​ 27,693 Derivative asset - forward purchase agreement at December 31, 2021 ​ $ 35,840 Change in fair value of derivate instrument related to forward purchase agreement ​ 17,600 Derivative asset - forward purchase agreement at March 31, 2022 ​ $ 53,440 Change in fair value of derivate instrument related to forward purchase agreement ​ ​ 73,760 Derivative asset - forward purchase agreement at June 30, 2022 ​ $ 127,200

Organization and Business Ope_2

Organization and Business Operations (Details)			3 Months Ended	6 Months Ended
	Feb. 18, 2021 USD ($) $ / shares shares	Nov. 26, 2020 item	Mar. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)
Subsidiary, Sale of Stock [Line Items]
Condition for future business combination number of businesses minimum | item		1
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares)	9,200,000
Proceeds from initial public offering | $				$ 92,000,000
Transaction Costs | $	$ 4,677,181
Underwriting fees | $	1,840,000
Deferred underwriting fee payable | $	2,300,000
Issuance of representative shares | $	920		$ 920
Other offering costs | $	$ 537,181
Investment of cash into Trust Account | $				$ 92,000,000
Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.1
Sponsor | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	3,642,222
Maxim | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	1,380,000
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares)	9,200,000
Purchase price, per unit | $ / shares	$ 10
Proceeds from initial public offering | $	$ 92,000,000
Number of shares in a unit	1
Number of shares issuable per warrant	1
Number Of Contingent Right	1
Non-redeemable Class A ordinary shares designated	92,000
Common Stock Value Designated | $	$ 920
Investment of cash into Trust Account | $	$ 92,000,000
Condition For Future Business Combination Threshold Percentage Ownership	100
Months to complete acquisition	24 months
Redemption period upon closure	185 days
Initial Public Offering | Warrants liabilities
Subsidiary, Sale of Stock [Line Items]
Share price | $ / shares	$ 11.50
Initial Public Offering | Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.2
Private Placement. | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	5,022,222
Price of warrant | $ / shares	$ 0.90
Proceeds from private placement | $	$ 4,520,000
Private Placement. | Sponsor
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	3,642,222
Private Placement. | Maxim
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	1,380,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Sale of Units, including over-allotment, net of fair value of warrant liability and offering costs (in shares)	1,200,000
Purchase price, per unit | $ / shares	$ 10

Significant Accounting Polici_4

Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Feb. 18, 2021	Dec. 06, 2020
Cash equivalents	$ 0	$ 0
Offering Costs Associated with Initial Public Offering	4,678,101
Offering Cost Charged to temporary Equity	4,472,203
Offering Cost	205,898
Federal Depository Insurance Coverage	250,000
Provision for income taxes	$ 0
Class A ordinary shares
Anti-dilutive securities attributable to warrants (in shares)	8,088,889
Class A ordinary shares subject to possible redemption
Ordinary shares, shares subject to possible redemption, issued (in shares)	9,200,000	9,200,000
Class B ordinary shares
Ordinary shares, shares subject to possible redemption, issued (in shares)			303,000	303,000

Significant Accounting Polici_5

Significant Accounting Policies - Calculation of basic and diluted net income (loss) per ordinary share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Allocation of net income (loss)	$ 1,569,634	$ 2,252,579	$ (1,543,021)	$ 1,446,358	$ 3,822,213	$ (96,663)
Class A ordinary shares
Allocation of net income (loss)	$ 1,255,707		$ (1,234,417)		$ 3,057,770	$ (77,330)
Weighted Average Ordinary Shares outstanding, Basic	9,292,000		9,292,000		9,292,000	6,776,486
Weighted Average Ordinary Shares outstanding, Diluted	9,292,000		9,292,000		9,292,000	6,776,486
Basic net income (loss) per ordinary share	$ 0.14		$ (0.13)		$ 0.33	$ (0.01)
Diluted net income (loss) per ordinary share	$ 0.14		$ (0.13)		$ 0.33	$ (0.01)
Class B ordinary shares
Allocation of net income (loss)	$ 313,927		$ (308,604)		$ 764,443	$ (19,333)
Weighted Average Ordinary Shares outstanding, Basic	2,323,000		2,323,000		2,323,000	2,240,972
Weighted Average Ordinary Shares outstanding, Diluted	2,323,000		2,323,000		2,323,000	2,240,972
Basic net income (loss) per ordinary share	$ 0.14		$ (0.13)		$ 0.33	$ (0.01)
Diluted net income (loss) per ordinary share	$ 0.14		$ (0.13)		$ 0.33	$ (0.01)

IPO (Details)

IPO (Details)	Feb. 18, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold	9,200,000
Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.1
Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of shares in a unit	1
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of units sold	9,200,000
Purchase price, per unit | $ / shares	$ 10
Number of shares in a unit	1
Initial Public Offering | Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.2
Initial Public Offering | Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of units sold	9,200,000
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of units sold	1,200,000
Purchase price, per unit | $ / shares	$ 10

IPO - Ordinary share subject to

IPO - Ordinary share subject to possible redemption reflected on the balance sheet (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
IPO
Gross proceeds from public issuance	$ 92,000,000
Proceeds allocated to Public Warrants		$ (4,089,353)
Class A ordinary shares issuance costs		(4,471,283)
Accretion of carrying value to redemption value	80,767	8,560,636
Class A ordinary shares subject to possible redemption shares	$ 92,080,767	$ 92,000,000

Private Placement (Details)

Private Placement (Details)	Feb. 18, 2021 USD ($) $ / shares shares
Private Placement Warrants | Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of shares per warrant	1
Share price | $ / shares	$ 11.50
Sponsor | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,642,222
Maxim | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	1,380,000
Private Placement. | Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	5,022,222
Price of warrants | $ / shares	$ 0.90
Aggregate purchase price | $	$ 4,520,000
Private Placement. | Sponsor
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	3,642,222
Private Placement. | Maxim
Subsidiary, Sale of Stock [Line Items]
Number of warrants to purchase shares issued	1,380,000

Related Party Transactions - Fo

Related Party Transactions - Founder Shares (Details)		6 Months Ended
	Feb. 18, 2021 D $ / shares shares	Jun. 30, 2022 USD ($) D $ / shares shares
Related Party Transaction [Line Items]
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination		20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination		30
Founder shares | Sponsor | Class B ordinary shares
Related Party Transaction [Line Items]
Number of shares issued | shares		2,323,000
Aggregate purchase price | $		$ 25,000
Per share dividend | $ / shares		$ 0.01
Aggregate number of shares owned | shares		303,000
Shares subject to forfeiture | shares	303,000
Restrictions on transfer period of time after business combination completion	1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares	$ 12
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination	20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination	30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences	150 days

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended
	Feb. 18, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 07, 2020
Related Party Transaction [Line Items]
Working capital loans				$ 2,000,000
Private placement warrant				$ 0.90
Derivative liability current	$ 521,597
Fair Value Adjustment of Warrants		$ (1,673,968)	$ 1,354,886	$ (4,134,101)	$ (405,151)
Forward purchase agreement
Related Party Transaction [Line Items]
Fair Value Adjustment of Warrants		91,360	229,644	73,760	8,147
Derivative Asset		$ 127,220		$ 127,220
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Derivative Assets Forward Purchase Agreement		Derivative Assets Forward Purchase Agreement
Promissory Note with Related Party
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note							$ 300,000
Outstanding balance of related party note		$ 0		$ 0
Repayment of promissory note - related party	$ 300,000
Administrative Support Agreement
Related Party Transaction [Line Items]
Expenses per month				10,000
Expenses incurred and paid		30,000		60,000
Administrative service fee			$ 30,000		$ 45,714
Outstanding due		0		0		$ 0
Related Party Loans
Related Party Transaction [Line Items]
Loan conversion agreement warrant		$ 16,000,000		$ 16,000,000
Purchase units				1,600,000
Related Party Loans | Working capital loans warrant
Related Party Transaction [Line Items]
Price of warrant		$ 10		$ 10

Related Party Transactions - Sc

Related Party Transactions - Schedule Of Derivative Instruments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Subsidiary, Sale of Stock [Line Items]
Change in fair value of derivate instrument related to forward purchase agreement	$ (1,673,968)	$ 1,354,886	$ (4,134,101)	$ (405,151)
Forward purchase agreement
Subsidiary, Sale of Stock [Line Items]
Change in fair value of derivate instrument related to forward purchase agreement	91,360	$ 229,644	73,760	$ 8,147
Derivative asset - forward purchase agreement	$ 127,220		$ 127,220

Commitments and Contingencies (

Commitments and Contingencies (Details)		6 Months Ended
	Feb. 18, 2021 USD ($) shares	Jun. 30, 2022 USD ($) item
Commitments and Contingencies.
Maximum number of demands for registration of securities | item		3
Underwriting cash discount per unit		2%
Underwriter cash discount		$ 1,840,000
Underwriting discount		2.50%
Aggregate underwriter cash discount		$ 2,300,000
Non-redeemable Class A ordinary shares | shares	92,000
Estimated the fair value	$ 920

Derivative Liability (Details)

Derivative Liability (Details) - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Feb. 18, 2021
Subsidiary, Sale of Stock [Line Items]
Exercisable on the later				5 years
Public warrants expire				30 days
Weighted average trading days				20 days
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)				115%
Ordinary share adjusted				$ 18
Warrant liability	$ 1,892,587	$ 3,492,795	$ 8,212,349	$ 1,892,587	$ 5,935,328	$ 10,851,878
Change in fair value of warrant liabilities	$ 1,600,208	$ 2,442,533	$ 2,639,529		$ 2,277,021
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants		Fair Value Adjustment of Warrants
Minimum
Subsidiary, Sale of Stock [Line Items]
Weighted average trading days				30 days
Warrant price				$ 0.10
Class A ordinary shares
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants	$ 11.50			11.50
Effective issue price				$ 9.20
Total equity proceeds				60%
Weighted average trading days				20 days
Higher of the Market Value				180%
Newly issued price				$ 18
Ordinary share equals or exceeds				18
Redemption trigger price				10
Ordinary share adjusted				$ 10
Market value and the newly issued price				100%
Redeemable Warrant				$ 0.3611
Ordinary share exercisable				$ 18
Threshold period for registration statement to be effective after which warrants can be exercised on a cashless basis				60 days
Warrant price				$ 0.01
Public share				10
Class A ordinary shares | Public Warrants
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants	$ 9.20			$ 9.20
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Public warrants expire				12 months
Initial Public Offering And Private Placement
Subsidiary, Sale of Stock [Line Items]
Common shares, issued (in shares)	8,088,888			8,088,888	8,088,888

Derivative Liability - Change i

Derivative Liability - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Dec. 31, 2021
Derivative Liability.
Fair value at the beginning	$ 3,492,795	$ 5,935,328	$ 10,851,878	$ 8,212,349
Change in fair value of warrant liabilities	$ (1,600,208)	$ (2,442,533)	$ (2,639,529)	$ (2,277,021)
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants
Fair value at the ending	$ 1,892,587	$ 3,492,795	$ 8,212,349	$ 5,935,328

Shareholders' Deficit - Preferr

Shareholders' Deficit - Preferred Stock Shares (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Shareholders' Deficit
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0

Shareholders' Deficit - Common

Shareholders' Deficit - Common Stock Shares (Details) - USD ($)	Dec. 06, 2020	Jun. 30, 2022	Dec. 31, 2021	Feb. 18, 2021
Class A ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		200,000,000	200,000,000
Common shares, par value (in dollars per share)		$ 0.0001	$ 0.0001
Class A ordinary shares subject to possible redemption
Class of Stock [Line Items]
Ordinary shares, shares subject to possible redemption, issued (in shares)		9,200,000	9,200,000
Class A common stock subject to possible redemption, outstanding (in shares)		9,200,000	9,200,000
Class A ordinary shares not subject to possible redemption
Class of Stock [Line Items]
Common shares, issued (in shares)		92,000	92,000
Common shares, shares outstanding (in shares)		92,000	92,000
Class B ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)		20,000,000	20,000,000
Common shares, par value (in dollars per share)	$ 0.01	$ 0.0001	$ 0.0001
Common shares, issued (in shares)		2,323,000	2,323,000
Common shares, shares outstanding (in shares)		2,323,000	2,323,000
Ordinary shares, shares subject to possible redemption, issued (in shares)	303,000			303,000
Sponsor paid	$ 25,000

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional information (Details)	6 Months Ended
	Jun. 30, 2022 D $ / shares
Class of Warrant or Right [Line Items]
Warrant exercise period condition one	1 year
Warrant exercise period condition two	150 days
Redemption price per public warrant (in dollars per share) | $ / shares	$ 12
Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days	20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination	30
Class B ordinary shares
Class of Warrant or Right [Line Items]
Period of time within which registration statement is expected to become effective	20%

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Assets:
Asset Held In Trust Account	$ 92,080,767	$ 92,008,585
Derivative asset - forward purchase agreement	127,200	35,840
Assets	92,207,967	92,044,425
Liabilities:
Warrant Liability	1,892,587	5,935,328
Public Warrants
Liabilities:
Warrant Liability	235,112	746,324
Private Placement Warrants
Liabilities:
Warrant Liability	1,657,475	5,189,004
Level 1
Assets:
Asset Held In Trust Account	92,080,767	92,008,585
Assets	92,080,767	92,008,585
Liabilities:
Warrant Liability		746,324
Level 1 | Public Warrants
Liabilities:
Warrant Liability		746,324
Level 2
Liabilities:
Warrant Liability	235,111
Level 2 | Public Warrants
Liabilities:
Warrant Liability	235,111
Level 3
Assets:
Derivative asset - forward purchase agreement	127,200	35,840
Assets	127,200	35,840
Liabilities:
Warrant Liability	1,657,475	5,189,004
Level 3 | Private Placement Warrants
Liabilities:
Warrant Liability	$ 1,657,475	$ 5,189,004

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Fair Value Measurements Inputs (Details)	1 Months Ended
	Apr. 30, 2021 USD ($)	Jun. 30, 2022 Y	Dec. 31, 2021 Y
Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value of the Public Warrants transferred from a Level 3 | $	$ 891,000
Exercise price | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		11.5	11.5
Share price | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		9.78	9.72
Volatility | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		2.7	12.1
Expected life | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input | Y		5.32	5.57
Risk-free rate | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		3.01	1.31
Dividend yield | Level 3 | Public and Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input		0	0

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative information relating to fair value measurements of forward purchase agreements (Details) - Forward Purchase Agreement - Level 3	Jun. 30, 2022 Y	Dec. 31, 2021 Y
Share price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward Purchase Agreement, measurement input	9.78	9.72
Forward Purchase Price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward Purchase Agreement, measurement input	10	10
Expected life
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward Purchase Agreement, measurement input	0.32	0.57
Risk-free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward Purchase Agreement, measurement input	1.94	0.22
NPV of Per-Share Commitment
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Forward Purchase Agreement, measurement input	9.94	9.99

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of change in fair value of liabilities which are classified as level 3 (Details) - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning	$ 3,492,795	$ 5,935,328	$ 10,851,878	$ 8,212,349
Change in fair value	$ 1,600,208	$ 2,442,533	$ 2,639,529	$ 2,277,021
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants	Fair Value Adjustment of Warrants
Fair value at the ending	$ 1,892,587	$ 3,492,795	$ 8,212,349	$ 5,935,328	$ 8,212,349
Level 3 | Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning	3,056,920	5,189,004		8,212,349	0
Initial value of public and private warrant liabilities					10,851,878
Initial value of FPA					521,597
Public Warrants reclassified to level 1				(891,000)
Change in fair value	(1,399,445)	(2,132,084)		(2,132,345)	(2,639,529)
Fair value at the ending	$ 1,657,475	$ 3,056,920	$ 8,212,349	$ 5,189,004	$ 8,212,349

Fair Value Measurements - Chang

Fair Value Measurements - Changes in the fair value of FPA Derivative (Asset) liability (Details) - Forward purchase agreement - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value at the beginning	$ 53,440	$ 35,840	$ (521,597)	$ 8,147
Change in fair value	73,760	17,600	529,744	27,693
Fair value at the ending	$ 127,200	$ 53,440	$ 8,147	$ 35,840